Abstract:

Objective To observe the short-time efficacy and safety of regimen containing rifabutin (Rfb) in patients with slowly growing mycobacterium (SGM) lung disease.Methods One hundred and twenty-four inpatients with SGM lung disease treated with standard regimen and regular management who hospitalized in shanghai pulmonary hospital from January 2013 to December 2014 were enrolled in this retrospective study. Fifty-six patients were treated with Rfb regimen as observation group and 68 patients were treated without Rfb regimen as control group. The treatment outcome and drug adverse reaction rates were compared between the two groups.Results (1) The sputum negative conversion rate in the end of 12 months in the observation group was (78.57%,44/56) significantly higher than that in the control group (69.12%,47/68) (χ ²=3.098, P=0.008). There were no statistic significance of the sputum negative conversion rates in the end of 3 months and 6 months between the two groups (all P value >0.05). (2) The focal absorption rate (75.00%,42/56)in the observation group was significantly higher than that (60.29%,41/68) in the control group (χ ²=4.523, P=0.009). There was no statistic significance of the lung cavity closure rate between the two groups (χ ²=1.952, P=0.094). Compared with the control group on the focus absoption rate (60.29%, 41/68), the observation group (73.21%, 41/56) had a better efficacy (χ ²=3.412, P=0.012).Conclusion Regimen containing Rfb shows a better short-time efficacy in the treatment of patients with SGM lung disease. However, the drug adverse reaction rates in observation group are higher than those in control group.

Key words: Mycobacterium infections, atypical, Rifabutin, Drug therapy, combination, Clinical protocols, Comparative effectiveness research